Evidence map›Paper›PMID 36831876›Full record

ArticleBrain sciences2023

Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists.

M A Alvarez-Mon, Cielo García-Montero, Oscar Fraile-Martinez, Javier Quintero, Sonia Fernandez-Rojo, Fernando Mora, Luis Gutiérrez-Rojas, Rosa M Molina-Ruiz, Guillermo Lahera, Melchor Álvarez-Mon and 1 more

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

M A Alvarez-MonDepartment of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0002-1987-0394
Cielo García-MonteroDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0001-6016-7855
Oscar Fraile-MartinezDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0002-4494-6397
Javier QuinteroDepartment of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.
Sonia Fernandez-RojoDepartment of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0003-0653-8808
Fernando MoraDepartment of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0003-4698-1679
Luis Gutiérrez-RojasDepartment of Psychiatry, University of Granada, 18016 Granada, Spain.ORCID 0000-0003-0082-2189
Rosa M Molina-RuizDepartment of Psychiatry and Mental Health, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain.
Guillermo LaheraDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0002-6152-3564
Melchor Álvarez-MonDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-1309-7510
Miguel A OrtegaDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-2588-1708
Universidad de Alcalá · ESUniversidad Complutense de Madrid · ESUniversidad de Granada · ES

Funding

Comunidad de Madrid P2022/BMD-7321
6 · The paper itself

Abstract

Major depressive disorder (MDD) is a complex psychiatric disorder that, presented alone or with other comorbidities, requires different adjustments of antidepressant treatments. Some investigations have demonstrated that psychoactive drugs, such as serotonin and norepinephrine reuptake inhibitors (SNRIs), can exert more effective and faster antidepressant effects than other common medications used, such as serotonin selective reuptake inhibitors (SSRIs), although these differences are still controversial. During the last five years, the SNRI duloxetine has shown favorable results in clinical practice for the treatment of MDD, anxiety, and fibromyalgia. Through an online self-completed survey, in the present article, we collected information from 163 psychiatrists regarding the use of duloxetine and its comparison with other psychiatric drugs, concerning psychiatrists' knowledge and experience, as well as patients' preferences, symptoms, and well-being. We discussed and contrasted physicians' reports and the scientific literature, finding satisfactory concordances, and finally concluded that there is agreement regarding the use of duloxetine, not only due to its tolerability and effectiveness but also due to the wide variety of situations in which it can be used (e.g., somatic symptoms in fibromyalgia, diabetes) as it relieves neuropathic pain as well.

Indexed as

duloxetinemajor depressive disorder (MDD)real world dataserotonin and norepinephrine reuptake inhibitors (SNRIs)

Identifiers

PMID36831876
PMCPMC9953910
OpenAlexW4320917441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.